August 17, 2010 — Idebenone does not appear to improve neurologic function in pediatric patients with Friedreich's ataxia, according to the findings of a randomized phase 3 trial. David R. Lynch, MD, ...
Potential Positives Biogen has initiated the BRAVE study, a global Phase 3 clinical trial to evaluate omaveloxolone in children with Friedreich ataxia, addressing a critical unmet need in the ...
Larimar Therapeutics has initiated dosing for adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for nomlabofusp, a potential treatment for Friedreich’s ataxia. Adolescents who ...
CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...
Larimar Therapeutics, Inc. (LRMR) announced an update on their ongoing clinical study. This early-stage clinical trial, officially titled “A Phase 1 Study to Assess the Safety, Tolerability, ...
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to 16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results